CeriBell (NASDAQ:CBLL) Director Joseph Michael Taylor Sells 5,500 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 5,500 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $18.41, for a total value of $101,255.00. Following the completion of the sale, the director owned 61,573 shares in the company, valued at $1,133,558.93. The trade was a 8.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

CeriBell Trading Up 0.6%

Shares of NASDAQ:CBLL opened at $18.59 on Tuesday. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $24.33. The company has a market capitalization of $705.30 million, a PE ratio of -11.40 and a beta of 0.85. The business has a 50 day moving average of $18.98 and a two-hundred day moving average of $19.71. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The firm had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. As a group, analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on CBLL shares. Canaccord Genuity Group decreased their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus target price of $22.20.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in shares of CeriBell during the 1st quarter worth about $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell during the 3rd quarter worth approximately $33,000. CWM LLC raised its holdings in shares of CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.